EMEA Presentation 2 (2009-10-22)

The purposes of the presentation is to demonstrate and present Drugle and Seibo's to EMEA and the PIM project.

Participants

Chairman:

  • Magnus Gruvén

Demonstrator:

  • Paul Cohen assisted by Daniel Rodríguez.

EMEA participants:

  • Morwena Gould (EMEA, PIM project).
  • Jill Newton (EMEA, PIM project).
  • Mark ? (EMEA, PIM project).

Practicalities

Time: 9:00 - 11:00 (GMT) UK

The meeting is takes place using the Vitero Virtual Conference program.

We should be logged in to the Viter/EMEA Drugle Demo virtual conference room by 9:45 (Stockholm time).

Agenda

0. Rationale: From what we know of your project and work, we believe that our tool can be of assistance in your work.

1. Verbal presentation based on the contents of the first Wiki page, ie the summary project description! Current work:

  • New source: All SPC:s from Läkemedelsverket (Sweden).
  • New source: SFINX Evidence based database with interaction informations (Sweden & Finland).
  • New terminology data: ATC, Drug names and substances, MedDRA.
  • New feature: Extraction and presentation of SPC section 4.8 undesirable effects tables.
  • New features: Presentation and GUI widgets.
  • Specification: Web service API (HTTPbased REST API).

2. Demonstrate drugledemo.seibostudios.se. Don't show in broad browser window! Caveat: this demo is not specially adapted for EMEA. The following searches can be shown:

  • "abdominal pain" (Normal profile & Doctor). Note: MHRA & EMEA, Search hits are sections in SPC, Note difference in "Normal" and "Doctor" profiles. Expand sections without browsing.
  • "dukoral (Normal profile). Note: Different EMEA languages. Advanced -> Search english.
  • "trombyl". Note: No SPC since Trombyl is a Swedish product name and we have not yet included Swedish Drug Agencies SPC:s. We do get a hit in Kloka listan which a shortlist of recommended drugs published by the Healthcare Department of the Stockholm City Council.
  • "ramipril". Note: c02ea05 INVALID ATC CODE. This ATC code is invalid. It may have been valid previously.

3. Possible amendments to Drugle that could aid the EMEA project:

  • Create a separate password protected Drugle installation tailored for EMEA use. EMEA Drugle!
  • Use only SPC:s and EMEA ADR reports as the indexed sources for EMEA Drugle.
  • Develop a EMEA ADR analytics profile that gives highest relevance to SPC sections 4.8 and 4.4.
  • Improve search relevance ratings based on for example ATC codes, pharmacotherapeutic group, MedDRA system organ class and frequency ratings.
  • An automated process for ADR signal detection based on indexing new ADR:s every night could be set up.
  • Note that some of the indexing & analysis tools have discovered formatting problems in the SPC PDF files (missing section 4.8)
  • User accounts and login. Personalized profiles.

4. Discussion. Emphasize:

  • We have long experience of working with medical informatics.
  • We are are approaching the problem from a software engineering/algorithmic perspective.
  • We are not applying data warehousing techniques, which often lead to huge data synchronization problems. We are focusing of information retrieval from existing online data.
  • We are applying state-of-the art Google style search algorithms (probabilistic search models) and modern sorting and relevance analysis tools.
  • We implement adaptive algorithms that can continously be improved via terminology analysis and profile and filter development.
  • We are currently working on including all SPC:s from all drug approval agencies in EU.
  • We are currently working on extracting and indexing the contents of the following SPC sections that are important in supporting pharmacological vigilance:
    • 4.8 (Undesirable Effects).
    • 4.4 (Special warnings and precautions for use).
    • 4.5 (Interaction with other medicinal products and other forms of interaction).
    • 4.6 (Pregnancy and lactation).
  • We are looking for participating and funding partners with an interest in our services and tools.